EBMT 2018 | EBMT 2018: Investigating breakthrough therapies for treating AML in adults

Charles Craddock

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, from University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, outlines the breakthrough therapies for the treatment of acute myeloid leukemia (AML) in adults, including midoastaurin in patients with a FLT-3 mutation, vyxeos for patients with secondary AML, and IDH2 inhibitors. This video was recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal.

Share this video